[Stage-dependent treatment of seminomas].
Stadienabhängige Therapie des Seminoms.
Chemotherapy
Germ cell neoplasm
PET-CT
Primary retroperitoneal lymph node dissection
Radiotherapy
Journal
Urologie (Heidelberg, Germany)
ISSN: 2731-7072
Titre abrégé: Urologie
Pays: Germany
ID NLM: 9918384886606676
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
accepted:
02
09
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
aheadofprint
Résumé
Germ cell neoplasms of the testis are rare solid tumors predominantly in young men. Seminomas are slightly more frequent than nonseminomatous germ cell tumors. A special feature of seminomas is that they are sensitive to radiation, so that this represents an option in tumor stages with few metastases; however, the guideline recommendation is cautious due to the increased risk of secondary malignancies. In nonmetastasized tumor stages active surveillance is the primary approach to avoid overtreatment of patients. This is also the reason for primary nerve-sparing retroperitoneal lymph node dissection in cases of a low metastasis load. This concept has already been implemented in the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) guidelines, whereas in the European Association of Urology (EAU) guidelines it is still considered to be an individual approach. Keimzelltumoren des Hodens sind eine seltene Tumorentität vornehmlich des jungen Mannes. Seminome sind etwas häufiger als nichtseminomatöse Keimzelltumoren. Als Besonderheit des Seminoms ist die Strahlensensibilität hervorzuheben, sodass dies eine Option bei gering metastasierten Tumorstadien darstellt. Die Leitlinienempfehlung ist jedoch zurückhaltend aufgrund des Risikos von Zweittumoren. Im nichtmetastasierten Tumorstadium ist die aktive Überwachung die primäre Vorgehensweise zur Vermeidung einer Übertherapie der Patienten. Dies ist auch der Hintergrund einer primären retroperitonealen Lymphadenektomie bei geringer Metastasenlast. In den Leitlinien der American Urological Association (AUA) und des National Comprehensive Cancer Network (NCCN) hat sich dieses Konzept bereits durchgesetzt, während es in den Leitlinien der European Association of Urology (EAU) noch als individuelles Vorgehen angesehen wird.
Autres résumés
Type: Publisher
(ger)
Keimzelltumoren des Hodens sind eine seltene Tumorentität vornehmlich des jungen Mannes. Seminome sind etwas häufiger als nichtseminomatöse Keimzelltumoren. Als Besonderheit des Seminoms ist die Strahlensensibilität hervorzuheben, sodass dies eine Option bei gering metastasierten Tumorstadien darstellt. Die Leitlinienempfehlung ist jedoch zurückhaltend aufgrund des Risikos von Zweittumoren. Im nichtmetastasierten Tumorstadium ist die aktive Überwachung die primäre Vorgehensweise zur Vermeidung einer Übertherapie der Patienten. Dies ist auch der Hintergrund einer primären retroperitonealen Lymphadenektomie bei geringer Metastasenlast. In den Leitlinien der American Urological Association (AUA) und des National Comprehensive Cancer Network (NCCN) hat sich dieses Konzept bereits durchgesetzt, während es in den Leitlinien der European Association of Urology (EAU) noch als individuelles Vorgehen angesehen wird.
Identifiants
pubmed: 39446232
doi: 10.1007/s00120-024-02446-9
pii: 10.1007/s00120-024-02446-9
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
B‑SNa BJK (2017) Epidemiologie bösartiger Hodentumoren in Deutschland. Onkologe: 2390–2396
Matei DV, Vartolomei MD, Renne G, Tringali VML, Russo A, Bianchi R et al (2017) Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did We Learn? Clin Genitourin Cancer 15(4):e689–e96
doi: 10.1016/j.clgc.2017.01.012
pubmed: 28216275
Paffenholz P, Held L, Loosen SH, Pfister D, Heidenreich A (2018) Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches. J Urol 200(2):353–360
doi: 10.1016/j.juro.2018.03.007
pubmed: 29530784
EAU (2018) EAU Guidlines on testicular cancer. Eur Assiciation Urol
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M et al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20(22):4448–4452
doi: 10.1200/JCO.2002.01.038
pubmed: 12431967
Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C et al (2018) Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol 73(3):394–405
doi: 10.1016/j.eururo.2017.09.025
pubmed: 29100813
Boormans JL, Sylvester R, Anson-Cartwright L, Glicksman RM, Hamilton RJ, Hahn E et al (2023) Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol
Wagner T, Toft BG, Lauritsen J, Bandak M, Christensen IJ, Engvad B et al (2024) Prognostic Factors for Relapse in Patients With Clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study. J Clin Oncol 42(1):81–89
doi: 10.1200/JCO.23.00959
pubmed: 37683134
Ruf CG, Schmidt S, Kliesch S, Oing C, Pfister D, Busch J et al (2022) Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival‑a systematic review. World J Urol 40(12):2889–2900
doi: 10.1007/s00345-022-04145-6
pubmed: 36107211
pmcid: 9712330
Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A et al (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6):1200–1208
doi: 10.1200/JCO.2005.08.003
pubmed: 15718317
Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M et al (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110(1):256–263
doi: 10.1038/bjc.2013.551
pubmed: 24263066
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R et al (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962
doi: 10.1200/JCO.2009.26.4655
pubmed: 21282539
Dieckmann KP, Dralle-Filiz I, Matthies C, Heinzelbecker J, Bedke J, Ellinger J et al (2016) Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol 142(7):1599–1607
doi: 10.1007/s00432-016-2162-z
pubmed: 27116691
pmcid: 4899489
Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol : Off J Eur Soc Med Oncol 19(3):443–447
doi: 10.1093/annonc/mdm540
Terbuch A, Posch F, Annerer LM, Bauernhofer T, Pichler M, Szkandera J et al (2017) Long-term cardiovascular complications in stage I seminoma patients. Clin Transl Oncol 19(11):1400–1408
doi: 10.1007/s12094-017-1742-y
pubmed: 28852960
pmcid: 5635068
Mortensen MS, Bandak M, Kier MG, Lauritsen J, Agerbaek M, Holm NV et al (2017) Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. Cancer 123(7):1212–1218
doi: 10.1002/cncr.30458
pubmed: 27893934
Tandstad T, Stahl O, Dahl O, Haugnes HS, Hakansson U, Karlsdottir A et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol : Off J Eur Soc Med Oncol 27(7):1299–1304
doi: 10.1093/annonc/mdw164
Joffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Gabe R et al (2022) Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). J Clin Oncol 40(22):2468–2478
doi: 10.1200/JCO.21.01199
pubmed: 35298280
Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33(1):51–57
doi: 10.1200/JCO.2014.56.2116
pubmed: 25135991
Fung C, Dinh P Jr., Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB (2018) Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Adv Urol 2018:8671832
doi: 10.1155/2018/8671832
pubmed: 29670654
pmcid: 5835297
Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A et al (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 29(6):719–725
doi: 10.1200/JCO.2010.30.1044
pubmed: 21205748
Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA et al (2023) Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol 41(16):3009–3018
doi: 10.1200/JCO.22.00624
pubmed: 36913642
Heidenreich A, Paffenholz P, Hartmann F, Seelemeyer F, Pfister D (2024) Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). Eur Urol Oncol 7(1):122–127
doi: 10.1016/j.euo.2023.06.004
pubmed: 37438222
Hiester A, Che Y, Lusch A, Kuss O, Niegisch G, Lorch A et al (2023) Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol 84(1):25–31
doi: 10.1016/j.eururo.2022.10.021
pubmed: 36372627
Matulewicz RS, Benfante N, Funt SA, Feldman DR, Carver B, Doudt A et al (2024) Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum. J Urol 211(1):80–89
doi: 10.1097/JU.0000000000003697
pubmed: 37672753
Tachibana I, Alabd A, Tong Y, Piroozi A, Mahmoud M, Kern SQ et al (2023) Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward? J Clin Oncol 41(23):3930–3938
doi: 10.1200/JCO.22.01822
pubmed: 36730902
Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R et al (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21(6):1101–1106
doi: 10.1200/JCO.2003.06.065
pubmed: 12637477
Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Fare E et al (2015) Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol : Off J Eur Soc Med Oncol 26(4):657–668
doi: 10.1093/annonc/mdu447
Loriot Y, Texier M, Culine S, Flechon A, Thiery-Vuillemin A, Gravis G, The GETUG SEMITEP Trial et al (2022) De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Eur Urol 82(2):172–179
doi: 10.1016/j.eururo.2022.04.031
pubmed: 35599187
Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M et al (2022) Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(11):1441–1450
doi: 10.1016/S1470-2045(22)00564-2
pubmed: 36228644
de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15(5):1837–1843
doi: 10.1200/JCO.1997.15.5.1837
pubmed: 9164193
Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG (2005) Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther 5(5):869–874
doi: 10.1586/14737140.5.5.869
pubmed: 16221056
Ghoreifi ASS, Sheybaee F et al (2024) Post-chemotherapy retroperoitoneal lymph node dissection for testicular seminoma: experience from two large referral centers. J Urol 211(5S):e9
doi: 10.1097/01.JU.0001008660.87408.90.18
Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169(6):2126–2128
doi: 10.1097/01.ju.0000060121.33899.4b
pubmed: 12771733
Pfister D, Porres D, Matveev V, Heidenreich A (2015) Reduced morbidity in resection of residual tumors after chemotherapy for seminoma. Urol Ausg A 54(10):1402–1406
doi: 10.1007/s00120-014-3708-9
De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al (2004) 2‑18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22(6):1034–1039
doi: 10.1200/JCO.2004.07.188
pubmed: 15020605
Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F et al Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol 2018:JCO1800210
Belge G, Dumlupinar C, Nestler T, Klemke M, Torzsok P, Trenti E et al (2024) Detection of Recurrence through microRNA-371a–3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Clin Cancer Res 30(2):404–412
doi: 10.1158/1078-0432.CCR-23-0730
pubmed: 37967143
Seelemeyer F, Pfister D, Pappesch R, Merkelbach-Bruse S, Paffenholz P, Heidenreich A (2023) Evaluation of a miRNA-371a–3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol